Establishing a diagnostic tool is essential to support the patient’s medical record. For instance, the diagnostic result is interpreted from the herbal dosage chart to determine the right amount of single herbs assigned to each patient’s condition are prescribed by the naturopathic doctor. Our clinical studies are to recruit patients to validate our scientific claims: recognizing the potential net benefits of using our economically-savings products in the treatment of infertilities or gynecologic neoplasms.
The following recruitment clinical studies focus on different biological processes:
- To evaluate and demonstrate the effect of our herbal formulations to treat hormonal dysfunction conditions, such as:
- Endometriosis encounters by childbearing age women (n=50)
- Polycystic Ovarian Syndrome (PCOS) developed by childbearing age women (n=50)
- Premature Ovarian Insufficiency (POI) observed in childbearing age women (n=50)
- Hyperprolactinemia women having blood serum prolactin level not exceeding levels recorded by adenoma (n=50)
- To evaluate and demonstrate the effect of our herbal formulations to recover noncancerous tumors, such as:
- Uterine fibroids in young women make it difficult to become pregnant (n=50)
- Salpingitis in young women prevent/reduce pregnancy outcome (n=50)
- Benign ovarian tumors and cysts cause infertility or symptoms (n=50)
- Uterine symptoms during menopause period (n=50)
- To evaluate and demonstrate the effect of our herbal formulations to reduce precancerous tumors, such as:
- Atypical endometrial hyperplasia occurs in women of any age, e.g. between menses, during menopause and post-menopause (n=100)
- Abnormal squamous and glandular cervical cells covers women of any age (n=100)
- To evaluate and demonstrate the therapeutic effect of our herbal formulations to alleviate cancerous tumors, such as
- Endometrial carcinomas mainly occur after menopause (n=100)
- Squamous and adenocarcinoma cervical cancers affect women across ages (n=100)
- Assessing the therapeutic effect of an herbal-drugs formulation as an effective approach to treat endometrioid carcinomas, such as
- Staging endometrial cancers selected across age groups (n=100)
- Staging endometrial cancers selected across age groups (n=100)